Table of Contents

doi : 10.1016/S0923-7534(25)00154-1

Volume 36, Issue 5, May 2025, Pages i-ii

خرید پکیج و مشاهده آنلاین مقاله

Editorial Board

doi : 10.1016/S0923-7534(25)00139-5

خرید پکیج و مشاهده آنلاین مقاله

FOxTROT: is anti-EGFR a good dancing partner?

doi : 10.1016/j.annonc.2025.02.001

خرید پکیج و مشاهده آنلاین مقاله

Going forward in pleural mesothelioma: time for a shift from a single-entity treatment approach

doi : 10.1016/j.annonc.2025.01.019

خرید پکیج و مشاهده آنلاین مقاله

Lessons from TROPiCS-04: ‘safety-first’ for success in late-stage clinical trials

doi : 10.1016/j.annonc.2025.02.008

خرید پکیج و مشاهده آنلاین مقاله

Telisotuzumab vedotin and osimertinib: the METamorphosis of epidermal growth factor receptor-mutant lung cancer?

doi : 10.1016/j.annonc.2025.01.008

خرید پکیج و مشاهده آنلاین مقاله

Enhancing radiotherapy with PARP inhibition in soft-tissue sarcomas: a promising synergy requiring specific attention to normal tissues?

doi : 10.1016/j.annonc.2025.02.007

خرید پکیج و مشاهده آنلاین مقاله

Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

doi : 10.1016/j.annonc.2025.02.006

خرید پکیج و مشاهده آنلاین مقاله

Efficacy assessment in phase I clinical trials: endpoints and challenges

doi : 10.1016/j.annonc.2025.02.010

خرید پکیج و مشاهده آنلاین مقاله

Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population☆

doi : 10.1016/j.annonc.2024.12.013

خرید پکیج و مشاهده آنلاین مقاله

The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study

doi : 10.1016/j.annonc.2024.12.015

خرید پکیج و مشاهده آنلاین مقاله

Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials

doi : 10.1016/j.annonc.2025.01.006

خرید پکیج و مشاهده آنلاین مقاله

A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial

doi : 10.1016/j.annonc.2024.12.014

خرید پکیج و مشاهده آنلاین مقاله

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial

doi : 10.1016/j.annonc.2025.01.011

خرید پکیج و مشاهده آنلاین مقاله

Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials

doi : 10.1016/j.annonc.2025.01.017

خرید پکیج و مشاهده آنلاین مقاله

Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib

doi : 10.1016/j.annonc.2025.01.001

خرید پکیج و مشاهده آنلاین مقاله

Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study

doi : 10.1016/j.annonc.2025.01.016

خرید پکیج و مشاهده آنلاین مقاله

Comment on: A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial

doi : 10.1016/j.annonc.2025.02.002

خرید پکیج و مشاهده آنلاین مقاله

Reply to Letter to the Editor: ‘A phase III randomised trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 years results of the OPERA trial’ by J. Meyer, T. Koessler

doi : 10.1016/j.annonc.2025.02.003

خرید پکیج و مشاهده آنلاین مقاله